Somatostatin agonists for treatment of acromegaly

被引：79

作者：

Ben-Shlomo, Anat ^{[1
]}

Melmed, Shlomo ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

来源：

MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2008年 / 286卷 / 1-2期

关键词：

acromegaly; somatostatin analogs; efficacy; side effects;

D O I：

10.1016/j.mce.2007.11.024

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The discovery of somatotropin-release inhibitory factor (SRIF) in hypothalamic extract in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of additional somatostatin receptor ligands (SRL) as pharmacotherapy for acromegaly and other neuroendocrine tumors. Long-acting formulations of SRL (octreotide LAR Depot, lanreotide SR and lanreotide autogel) assure improved patient compliance with weekly up to monthly injections, and are commonly used as primary or adjuvant treatment of acromegaly. We review SRL currently available, emphasizing long-acting compounds and their efficacy in controlling acromegaly. Disease control is evaluated by biochemical markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects. (C) 2008 Published by Elsevier Ireland Ltd.

引用

收藏

页码：192 / 198

页数：7

相关论文

共 64 条

[1] The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly [J].

AlMaskari, M ;

Gebbie, J ;

KendallTaylor, P .

CLINICAL ENDOCRINOLOGY, 1996, 45 (04) :415-421

[2] Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly [J].

Amato, G ;

Mazziotti, G ;

Rotondi, M ;

Iorio, S ;

Doga, M ;

Sorvillo, F ;

Manganella, G ;

Di Salle, F ;

Giustina, A ;

Carella, C .

CLINICAL ENDOCRINOLOGY, 2002, 56 (01) :65-71

[3] Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly [J].

Ambrosio, MR ;

Franceschetti, P ;

Bondanelli, M ;

Doga, M ;

Maffei, P ;

Baldelli, R ;

Tamburrano, G ;

Sicolo, N ;

Giustina, A ;

degli Uberti, E .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (03) :387-393

[4] Lanreotide 60 mg, a new long-acting formulation: Effectiveness in the chronic treatment of acromegaly [J].

Attanasio, R ;

Baldelli, R ;

Pivonello, R ;

Grottoli, S ;

Bocca, L ;

Gasco, V ;

Giusti, M ;

Tamburrano, G ;

Colao, A ;

Cozzi, R .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5258-5265

[5] Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy [J].

Ayuk, J ;

Stewart, SE ;

Stewart, PM ;

Sheppard, MC .

CLINICAL ENDOCRINOLOGY, 2004, 60 (03) :375-381

[6] Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly [J].

Ayuk, J ;

Stewart, SE ;

Stewart, PM ;

Sheppard, MC .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) :4142-4146

[7] Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients [J].

Baldelli, R ;

Ferretti, E ;

Jaffrain-Rea, ML ;

Iacobellis, G ;

Minniti, G ;

Caracciolo, B ;

Moroni, C ;

Cassone, R ;

Gulino, A ;

Tamburrano, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :527-532

[8] Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg) [J].

Baldelli, R ;

Colao, A ;

Razzore, P ;

Jaffrain-Rea, ML ;

Marzullo, P ;

Ciccarelli, E ;

Ferretti, E ;

Ferone, D ;

Gaia, D ;

Camanni, F ;

Lombardi, G ;

Tamburrano, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4099-4103

[9] Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment [J].

Baldelli, Roberto ;

Battista, Claudia ;

Leonetti, Frida ;

Ghiggi, Maria-Rosaria ;

Ribaudo, Maria-Cristina ;

Paoloni, Antonella ;

D'Amico, Eugenio ;

Ferretti, Elisabetta ;

Baratta, Roberto ;

Liuzzi, Antonio ;

Trischitta, Vincenzo ;

Tamburrano, Guido .

CLINICAL ENDOCRINOLOGY, 2003, 59 (04) :492-499

[10] TREATMENT OF RESISTANT ACROMEGALY WITH A LONG-ACTING SOMATOSTATIN ANALOG (SMS 201-995) [J].

BARNARD, LB ;

GRANTHAM, WG ;

LAMBERTON, P ;

ODORISIO, TM ;

JACKSON, IMD .

ANNALS OF INTERNAL MEDICINE, 1986, 105 (06) :856-861

← 1 2 3 4 5 6 7 →